Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 11% – Time to Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s stock price traded down 11% during mid-day trading on Thursday . The stock traded as low as GBX 676 and last traded at GBX 676. 21,518 shares changed hands during mid-day trading, a decline of 12% from the average session volume of 24,533 shares. The stock had previously closed at GBX 759.50.

Hemogenyx Pharmaceuticals Trading Up 7.5%

The stock has a market cap of £49.44 million, a P/E ratio of -4.26 and a beta of 1.53. The company has a debt-to-equity ratio of 167.66, a current ratio of 1.38 and a quick ratio of 6.72. The business’s 50 day simple moving average is GBX 753 and its 200 day simple moving average is GBX 827.53.

Hemogenyx Pharmaceuticals (LON:HEMO) last released its quarterly earnings data on Thursday, April 30th. The company reported GBX (170.60) earnings per share for the quarter.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.